Susquehanna Fundamental Investments
FATE icon

Susquehanna Fundamental Investments’s Fate Therapeutics FATE Stock Holding History

Susquehanna Fundamental Investments’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.3K Buy
+13,063
New +$24.2K ﹤0.01% 734
2025
Q2 		– Sell
-118,186
Closed -$93.4K – 826
2025
Q1 		$93.4K Hold
118,186
– – ﹤0.01% 1031
2024
Q4 		$195K Buy
+118,186
New +$298K ﹤0.01% 1010
2024
Q2 		$861K Buy
262,414
+111,293
+74% +$487K 0.02% 588
2024
Q1 		$1.11M Buy
+151,121
New +$935K 0.05% 330
2021
Q3 		– Sell
-35,693
Closed -$3.1M – 1753
2021
Q2 		$3.1M Sell
35,693
-7,000
-16% -$564K 0.06% 457
2021
Q1 		$3.52M Hold
42,693
– – 0.06% 450
2020
Q4 		$3.88M Hold
42,693
– – 0.07% 402
2020
Q3 		$1.71M Buy
42,693
+16,093
+61% +$562K 0.05% 479
2020
Q2 		$913K Buy
+26,600
New +$793K 0.04% 477

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna Fundamental Investments's FATE Position: Q2 2026 in Review

Susquehanna Fundamental Investments opened a new position in Fate Therapeutics (FATE) in Q2 2026: 13,063 shares worth $35.3K. The stake represents ﹤0.01% of the portfolio and ranks #734 among its holdings. This is a return to the name: Susquehanna Fundamental Investments previously reported a position in FATE as recently as Q1 2025.

Susquehanna Fundamental Investments first reported a position in FATE in Q2 2020 and has held it in 10 quarters since. The position peaked at $3.88M in Q4 2020. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Susquehanna Fundamental Investments held 13,063 shares of Fate Therapeutics worth $35.3K as of Q2 2026.
  • Fate Therapeutics was a new Susquehanna Fundamental Investments position in Q2 2026.
  • Fate Therapeutics made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q2 2026, its #734 holding.
  • Susquehanna Fundamental Investments first reported a position in Fate Therapeutics in Q2 2020 and has held it in 10 quarters since.
  • Susquehanna Fundamental Investments's Fate Therapeutics position peaked at $3.88M in Q4 2020.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2026, filed 14 Aug 2026.